IRulya Therapeutics Inc.
IRLA· Nasdaq
IRLAIRulya Therapeutics Inc.
Filed May 11, 2026 · 10-Q · 41 days after period end · 0001193125-26-217098
| Metric | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 |
|---|---|---|---|---|
| Net Income | $35.91M | -$15.03M | -$11.15M | -$12.25M |
| EPS Diluted | $2.88 | -$3.42 | -$0.26 | -$0.34 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
IRulya Therapeutics Inc. · CIK 1662774 · Engraved from SEC EDGAR
ended Mar 31, 2026 · filed May 11, 2026 · 41 d after period end
